A GUIDE TO ALPHA-1 ANTITRYPSIN DEFICIENCY

Similar documents
Could Your Asthma or COPD be Hereditary?

Alpha-1-antitrypsin deficiency

Pi ZZ Alpha 1 Antitrypsin Deficiency

Lung Disease: Genes and the Environment

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family

Lung Disease Note: You will need to provide paper towels for cleanup.

Alpha-1 Antitrypsin Deficiency Alpha-1 Lung Disease

Pi SZ Alpha 1 Antitrypsin Deficiency and other rarer types

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.

Corporate Medical Policy

Emphysema. Lungs The lungs help us breathe in oxygen and breathe out carbon dioxide. Everyone is born with 2 lungs: a right lung and a left lung.

Chronic Obstructive Pulmonary Disease A breathtaking condition

COPD. Helen Suen & Lexi Smith

written by Harvard Medical School COPD It Can Take Your Breath Away

Pharmacy Management Drug Policy

Alpha-1 Antitrypsin Deficiency AATD

Chronic Obstructive Pulmonary Disease. Gabrielle Matarazzo 5/2/2016

See Important Reminder at the end of this policy for important regulatory and legal information.

Partial Alpha 1 Antitrypsin Deficiency (Pi MZ)

Integrated Cardiopulmonary Pharmacology Third Edition

COPD COPD. C - Chronic O - Obstructive P - Pulmonary D - Disease OBJECTIVES

Infusion Management of Alpha-1 Antitrypsin Deficiency Patients. Alpha-1 Antitrypsin (AAT) the protein. AAT Deficiency (Alpha-1) 4/26/2013

Alpha-1 Antitrypsin Deficiency and Augmentation Therapy-Prolastin-C Post Test

Asthma. & Healthy Living FOR PATIENTS & CARERS. A guide to healthy habits and lifestyle choices for people with asthma

Chronic Obstructive Pulmonary Disease (COPD)

Augmentation Therapy. The Specific Therapy for Alpha-1 Lung Disease. Skinny Little Reference Guide

Genetic COPD: Understanding what we know, who we test, how we treat. M. Douglas Lee, MD FCCP Wilmington Health Associates Wilmington North Carolina

COPD. The goals of COPD. about. you quit. If you. efforts to quit. Heart

Pharmacy Advisor Program. Specialized Lung Health Support

Overview of COPD INTRODUCTION

Asthma. & Older Adults. A guide to living with asthma for people aged 65 years and over FOR PATIENTS & CARERS

RESPIRATORY CARE IN GENERAL PRACTICE

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Because we care about your health

Corporate Medical Policy

UNDERSTANDING & MANAGING

A patient educational resource provided by Boehringer Ingelheim Pharmaceuticals, Inc.

Biology Advanced Unit 5: Energy, Exercise and Coordination

COPD Research at the University of Maryland School of Maryland

11/27/18. Challenges in Pulmonary and Critical Care: Alpha-1 Antitrypsin Deficiency: New Hope for Diagnosis and Treatment. Faculty.

Thunderstorm Asthma. Protect yourself this pollen season Managing asthma and allergies matters

Get Healthy Stay Healthy

Alpha-1 Antitrypsin Deficiency: Liver Disease

Self-study course. Pneumonia

an inflammation of the bronchial tubes

Diseases caused by Smoking

FEP Medical Policy Manual

Reference Guide for Group Education

flu vaccination DRAFT The WINTER 2018/19 Who should have it and why Includes information for children and pregnant women mmunisation

Understanding Lung Problems Make Each Breath Healthy

Cough Associated with Bronchitis

Asthma Basic Facts. Staying safe and well with asthma. For people with asthma and their carers.

A Guide for Understanding Genetics and Health

Alpha-1 Antitrypsin Deficiency. Healthcare Provider s Guide

Asthma and Chronic Airways Disease

ALPHA-1 ANTITRYPSIN DEFICIENCY A HEALTHCARE PROVIDER S GUIDE

Living well with COPD

Understanding and Managing Your Chronic Obstructive Pulmonary Disease (COPD)* *Includes chronic bronchitis and emphysema.

It hurts you. It doesn t take much. It doesn t take long.

Medical History. Participant Id#: Acrostic: Tech ID#: Date: / / 1 How would you say your health currently compares with other persons of your age?

Large print version. Dr Ian Watson

Augmentation Therapy. The Specific Therapy for Alpha-1 Lung Disease. Skinny Little Reference Guide

Alpha1-register in Lithuania Brigita Sitkauskiene, MD, PhD

Subject: Alpha1-Proteinase Inhibitors (Human)

Wilson's Disease. A Guide. An explanation of what Wilson's disease is, symptoms, diagnosis and treatment

Year 2, 3 or 4 Asthma lesson presentation HARMFUL

Alpha-1 Antitrypsin Deficiency A Guide for the Recently Diagnosed Individual 1 ALPHA-1 FOUNDATION

Bronchitis. Anatomy of the Lungs The lungs allow us to fill our blood with oxygen. The oxygen we breathe is absorbed into our blood in the lungs.

flu vaccination The Who should have it and why WINTER 2017/18 Includes information for children and pregnant women mmunisation in England in 2017/18

Room # Critical Care & Pulmonary Consultants, P.C.

Chronic obstructive pulmonary disease

My life with COPD. English

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center

COPD. Living With Long-Term Lung Disease. COPD is a lung disease that. makes it harder to breathe. Doctors can help people

ALPHA 1 -PROTEINASE INHIBITORS

Disorder name: Severe Combined Immunodeficiency Acronym: SCID

COPD and other lung conditions

Chronic Obstructive Pulmonary Disease

Seasonal Flu Vaccination

Biochemistry of Lungs. Lecture # 35 Lecturer: Alexander Koval

Autosomal Dominant Polycystic Kidney Disease

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

Understanding Respiratory Illnesses

PATHOLOGY & PATHOPHYSIOLOGY

Running head: BEST-PRACTICE NURSING CARE FOR PATIENTS WITH 1 CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Asthma and COPD Awareness

Anyone who smokes and/or has shortness of breath and sputum production could have COPD

Asthma and COPD Awareness

Anaemia. The symptoms of anaemia are tiredness, shortness of breath and being pale. The anaemia in CDA is very variable.

X-Plain Lung Cancer Reference Summary

HealthPartners Care Coordination Clinical Care Planning and Resource Guide ASTHMA

Your Lungs and COPD. Patient Education Pulmonary Rehabilitation. A guide to how your lungs work and how COPD affects your lungs

Asthma. Guide to Good Health. Healthy Living Guide

Outpatient Guideline for the Diagnosis and Management of Asthma

Chronic Obstructive Pulmonary Disease

Policy #: 543 Latest Review Date: February 2017

Session Guidelines. This is a 15 minute webinar session for CNC physicians and staff

Transcription:

A GUIDE TO ALPHA-1 ANTITRYPSIN DEFICIENCY

DO YOU OR YOUR FAMILY MEMBERS SUFFER ANY OF THESE CONDITIONS? Asthma Jaundice Early onset emphysema Abnormal liver function Chronic bronchitis Recurrent chest colds Chronic Obstructive Pulmonary Disease (COPD) A family history of lung or liver issues YOUR CONDITION COULD BE CAUSED BY AN HEREDITARY CONDITION KNOWN AS ALPHA-1 ANTITRYPSIN DEFICIENCY, OR ALPHA-1. The Alpha-1 Association of Australia (AAA) is an organisation dedicated to the help and support of Australians who are affected by and interested in Alpha-1. 01

WHAT IS ALPHA-1? Alpha-1 is a genetic disorder which can cause lung or liver disease in children and adults. Alpha-1 is one of the most common hereditary disorders in the world, but it often remains undiagnosed. Knowing that you have Alpha-1 gives you the opportunity to avoid risk factors and to make positive lifestyle changes which, together with the right medical care, can help to improve your quality of life. Everyone s liver produces the protein alpha-1 antitrypsin, or AAT. An important function of AAT is to protect the lungs. In people with Alpha-1, the AAT is malformed and cannot be released by their liver. Alpha-1 occurs when there is a deficiency of AAT in the bloodstream. AAT also protects delicate lung tissue from an enzyme known as neutrophil elastase. The normal function of neutrophil elastase is to remove inhaled material which has entered the respiratory system, such as smoke and other pollutants. In the absence of AAT, neutrophil elastase will attack the harmful material as well as healthy lung tissue. Most commonly, this leads to lung disease, however, the build up of AAT in the liver can also lead to liver disease. The deficiency can cause problems with the pancreas and is associated with the skin disease panniculitis. However, problems with the lungs, and to a lesser degree the liver, are far more common. Not everyone who has Alpha-1 will develop symptoms. We still don t know why this is so, but we do know that early detection, treatment and lifestyle changes can make a dramatic difference in the progress of disease. As a result, the sooner a diagnosis is made, the more effective lifestyle and treatment options will be. 02

WHO IS AFFECTED BY ALPHA-1? As a genetic condition, Alpha-1 is passed from parents to children through genes. Everyone has two AAT genes, both being normal in most people. Those who suffer symptoms of Alpha-1 may have either one normal and one defective gene (known as carriers), or two defective genes. Approximately 1 in 37 worldwide have at least one defective gene*. In Australia it is estimated to be about 1 in 9. The severity of the disease varies between individuals, as AAT levels in the bloodstream may range between zero-80% of normal levels, depending on the number and type of affected genes an individual has. * Estimate based on data from: de Serres (2002), Chest, v. 122, p 1818-1829 03

WHAT ARE THE SIGNS AND SYMPTOMS OF ALPHA-1-RELATED DISEASE? The World Health Organisation makes the following recommendation with regard to testing for Alpha-1: It is therefore recommended that all patients with COPD and all adults and adolescents with asthma be screened once for AAT deficiency. Those with abnormal results on screening should have Pi (genetic) typing. Alpha-1 affects people in different ways and symptoms can vary between individuals. Some common early symptoms associated with lung or liver dysfunction include: Shortness of breath Decreased exercise tolerance Recurrent chest colds or respiratory/lung infections Chronic coughing and/or wheezing Excess sputum (phlegm) Asthma which is not responsive to treatment History of suspected allergies Abdominal swelling Abnormal liver function tests or unexplained liver problems Enlarged liver or spleen Skin lesions or inflammation Jaundice 04

HOW DO I GET TESTED FOR ALPHA-1? If you suffer from any symptoms listed in this brochure, you can ask your doctor for a simple blood test which is covered by the Medicare Benefits Scheme. The Medicare schedule numbers for Alpha-1 testing are as follows: 66635 - Quantitation in serum, urine or other bodily fluids 66638 - Isoelectric focussing or similar methods for determination of alpha-1 antitrypsin deficiency phenotype in serum 66635 will measure the level of AAT in your bloodstream. Low AAT levels may indicate a need for phenotyping (66638) or DNA testing to assess your individual AAT genetic makeup. If you have a relative who has been diagnosed with Alpha-1, or a family history of early emphysema or liver disease, phenotyping or DNA testing is recommended regardless of your AAT levels. This is because AAT levels alone do not necessarily reveal your AAT genetic status. Knowledge of AAT levels in conjunction with knowledge of your AAT genetic status allows a more complete understanding of the implications for you and your children or future children. Some with Alpha-1 may present without obvious symptoms and lead relatively healthy lives, especially if smoking is avoided. However, they still risk passing the defective gene on to their children. Those seeking Alpha-1 diagnosis for themselves or family members should carefully consider health and life insurance complications, for example an insurer s requirement for disclosure of known preexisting illnesses. 05

HOW DID I INHERIT ALPHA-1? NORMAL Alpha-1 MOTHER FATHER MOTHER MZ FATHER MZ CHILD 1 CHILD 2 CHILD 3 CHILD 4 CHILD 1 MZ CHILD 2 ZM CHILD 3 ZZ CHILD 4 Every human being is made up of many pairs of genes, and for each pair, we inherit one from each parent. Pi stands for protease inhibitor, of which AAT is just one. A normal person is referred to as Pi, i.e. they have two normal genes, which means they produce a normal supply of AAT. Sometimes a faulty gene is thrown into the mix. The most common abnormal gene is referred to as the Z gene (there are other variants, but since they all follow the same pattern, we ll stick with the Z). For someone to be PiZZ, a faulty gene must have been inherited from each parent, which means each parent must have had at least one Z gene (usually MZ). Alpha-1 occurs when both parents pass on an abnormal gene to their child. A mother and father who are both carriers, (eg. MZ), have a 50% chance of their child being a carrier, 25% chance of having a child without Alpha-1, (), or 25% probability of having a child with Alpha-1, (eg. ZZ). The same percentages apply for each child. Therefore, it is possible for an MZ father and an MZ mother to have four children, all of who are ZZ or all of who are. On the other hand, it is possible for this same father and mother to have 1 ZZ child, 2 MZ children and 1 child, as the percentages imply. If one parent has the ZZ phenotype, and the other has two normal copies of the gene (), all of their children will have the MZ phenotype. See example in the diagram above. 06

CAN ALPHA-1 BE TREATED? TREATMENT OF ALPHA-1 Two manufacturers have registered their respective augmentation therapy products with Australia s Therapeutic Goods Administration. These therapies are Zemaira by CSL Behring, and Prolastin-C by Grifols. As at time of this booklet s production, the cost of augmentation therapy makes it out of reach for most Australian patients. The manufacturers have lodged applications for funding with the National Blood Authority, and the AAA eagerly awaits the outcome. TREATMENT OF SYMPTOMS Treatment of the symptoms associated with Alpha-1 are many and varied, depending on the symptom. It is vital that the doctors involved with your care are aware of your Alpha-1 status, and the need to consider action at the first sign of related symptoms, for example bringing respiratory infections under control, in order to minimise long term damage. ORGAN TRANSPLANTATION AND OTHER SURGICAL PROCEDURES Should your Alpha-1 lead to severe lung or liver damage, a lung or liver transplant, or lung reduction therapy, may be an option for you. 07

WHAT IS MY FUTURE ONCE I AM DIAGNOSED WITH ALPHA-1? Early diagnosis of Alpha-1 represents an opportunity to take steps to avoid risk factors, limit symptoms, or slow the progression of symptoms you may already be experiencing. One of the things you should know is exactly which Alpha-1 genes you have. Without that knowledge, it is difficult to know how the diagnosis will affect either you or your family. Not everyone with Alpha-1 will develop symptoms. Even if you do experience symptoms, proper treatment by your doctors and lifestyle changes may significantly increase the quality and quantity of your life. 08

HOW CAN I IMPROVE MY CHANCES OF STAYING HEALTHY? Seek periodic liver and respiratory tests in order to help early identification of symptoms and to monitor progress Avoid cigarette smoking, fumes, dust, and other polluted environments, especially for extended periods, such as industrialised workplaces generating poor air quality Seek early treatment for lung infections and colds Seek your doctor s guidance in relation to vaccinating yourself against infectious diseases which may exacerbate the effects of Alpha-1 Ensure you have regular immunisations against influenza and pneumonia Stay fit with regular exercise Maintain a balanced diet Moderate, if not eliminate, intake of liver toxins such as alcohol Avoid non-essential intake of drugs - some over-the-counter drugs and certain prescribed medications can harm the liver 09

HOW CAN I HELP AAA? To help the AAA meet its objectives, you can help in various ways: Donations can be made via: CONTACT DETAILS Alpha-1 Association of Australia emailus@alpha1.org.au Become a AAA volunteer: Contact us to find out about current projects, including fundraising. Join the discussion: See the link to Discussions via 10

Document version 4 Updated Oct 2017 Disclaimer: The information published by the AAA is a guide only, and is not intended to be a substitute for professional medical or legal advice. The AAA, its officeholders and its members disclaim all liability from reliance placed on the information herein. For medical advice, please consult your physician. For legal advice, please consult your lawyer.